Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer

A safety, feasibility, and efficacy study from the Hoosier oncology group

Shadia Jalal, Pablo Bedano, Lawrence Einhorn, Sumeet Bhatia, Rafat Ansari, Naftali Bechar, Karuna Koneru, Ramaswamy Govindan, Jingwei Wu, Menggang Yu, Bryan Schneider, Nasser Hanna

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Bevacizumab when combined with carboplatin and paclitaxel improves response rates (RRs) and overall survival in patients with advanced non-small cell lung cancer. Paclitaxel has single-agent activity in relapsed small cell lung cancer (SCLC). Angiogenesis seems to play an important role in the pathogenesis of SCLC. This study evaluated the safety and efficacy of paclitaxel plus bevacizumab in patients with chemosensitive relapsed SCLC. Methods: Patients with relapsed chemosensitive SCLC with an Eastern Cooperative Oncology Group performance status of 0 to 1 were eligible. They received paclitaxel 90 mg/m2 intravenously on days 1, 8, and 15. Bevacizumab was administered at 10 mg/kg intravenously on days 1 and 15. Cycles were every 28 days. The primary endpoint was progression-free survival (PFS). Secondary endpoints included RRs, toxicity, and overall survival. Correlative studies evaluated vascular endothelial growth factor polymorphisms. Results: Thirty-four patients were enrolled in the study. Median age was 66.5 (range, 38-88) years, male:female: 61.8%:38.2%, Eastern Cooperative Oncology Group performance status 0:1 47.1%:52.9%. Median progression-free survival was 14.7 weeks (equivalent to historical controls). Median survival time was 30 weeks. The overall RR was 18.1%. Stable disease rate was 39.3%, and 45.4% of patients had progressive disease. No unexpected toxicities were noted, and grade 3/4 toxicities were limited to neutropenia, fatigue, and dyspnea. None of the vascular endothelial growth factor polymorphisms evaluated were significantly associated with response. Conclusions: The addition of bevacizumab to paclitaxel does not improve outcomes in relapsed chemosensitive SCLC.

Original languageEnglish
Pages (from-to)2008-2011
Number of pages4
JournalJournal of Thoracic Oncology
Volume5
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Small Cell Lung Carcinoma
Feasibility Studies
Paclitaxel
Safety
Vascular Endothelial Growth Factor A
Disease-Free Survival
Survival
Carboplatin
Neutropenia
Non-Small Cell Lung Carcinoma
Dyspnea
Fatigue
Survival Rate
Bevacizumab

Keywords

  • Bevacizumab
  • Paclitaxel
  • Relapsed small cell

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer : A safety, feasibility, and efficacy study from the Hoosier oncology group. / Jalal, Shadia; Bedano, Pablo; Einhorn, Lawrence; Bhatia, Sumeet; Ansari, Rafat; Bechar, Naftali; Koneru, Karuna; Govindan, Ramaswamy; Wu, Jingwei; Yu, Menggang; Schneider, Bryan; Hanna, Nasser.

In: Journal of Thoracic Oncology, Vol. 5, No. 12, 12.2010, p. 2008-2011.

Research output: Contribution to journalArticle

Jalal, Shadia ; Bedano, Pablo ; Einhorn, Lawrence ; Bhatia, Sumeet ; Ansari, Rafat ; Bechar, Naftali ; Koneru, Karuna ; Govindan, Ramaswamy ; Wu, Jingwei ; Yu, Menggang ; Schneider, Bryan ; Hanna, Nasser. / Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer : A safety, feasibility, and efficacy study from the Hoosier oncology group. In: Journal of Thoracic Oncology. 2010 ; Vol. 5, No. 12. pp. 2008-2011.
@article{f734da0ff5534af38b0ce928bd1ab27f,
title = "Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: A safety, feasibility, and efficacy study from the Hoosier oncology group",
abstract = "Bevacizumab when combined with carboplatin and paclitaxel improves response rates (RRs) and overall survival in patients with advanced non-small cell lung cancer. Paclitaxel has single-agent activity in relapsed small cell lung cancer (SCLC). Angiogenesis seems to play an important role in the pathogenesis of SCLC. This study evaluated the safety and efficacy of paclitaxel plus bevacizumab in patients with chemosensitive relapsed SCLC. Methods: Patients with relapsed chemosensitive SCLC with an Eastern Cooperative Oncology Group performance status of 0 to 1 were eligible. They received paclitaxel 90 mg/m2 intravenously on days 1, 8, and 15. Bevacizumab was administered at 10 mg/kg intravenously on days 1 and 15. Cycles were every 28 days. The primary endpoint was progression-free survival (PFS). Secondary endpoints included RRs, toxicity, and overall survival. Correlative studies evaluated vascular endothelial growth factor polymorphisms. Results: Thirty-four patients were enrolled in the study. Median age was 66.5 (range, 38-88) years, male:female: 61.8{\%}:38.2{\%}, Eastern Cooperative Oncology Group performance status 0:1 47.1{\%}:52.9{\%}. Median progression-free survival was 14.7 weeks (equivalent to historical controls). Median survival time was 30 weeks. The overall RR was 18.1{\%}. Stable disease rate was 39.3{\%}, and 45.4{\%} of patients had progressive disease. No unexpected toxicities were noted, and grade 3/4 toxicities were limited to neutropenia, fatigue, and dyspnea. None of the vascular endothelial growth factor polymorphisms evaluated were significantly associated with response. Conclusions: The addition of bevacizumab to paclitaxel does not improve outcomes in relapsed chemosensitive SCLC.",
keywords = "Bevacizumab, Paclitaxel, Relapsed small cell",
author = "Shadia Jalal and Pablo Bedano and Lawrence Einhorn and Sumeet Bhatia and Rafat Ansari and Naftali Bechar and Karuna Koneru and Ramaswamy Govindan and Jingwei Wu and Menggang Yu and Bryan Schneider and Nasser Hanna",
year = "2010",
month = "12",
doi = "10.1097/JTO.0b013e3181f77b6e",
language = "English",
volume = "5",
pages = "2008--2011",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "12",

}

TY - JOUR

T1 - Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer

T2 - A safety, feasibility, and efficacy study from the Hoosier oncology group

AU - Jalal, Shadia

AU - Bedano, Pablo

AU - Einhorn, Lawrence

AU - Bhatia, Sumeet

AU - Ansari, Rafat

AU - Bechar, Naftali

AU - Koneru, Karuna

AU - Govindan, Ramaswamy

AU - Wu, Jingwei

AU - Yu, Menggang

AU - Schneider, Bryan

AU - Hanna, Nasser

PY - 2010/12

Y1 - 2010/12

N2 - Bevacizumab when combined with carboplatin and paclitaxel improves response rates (RRs) and overall survival in patients with advanced non-small cell lung cancer. Paclitaxel has single-agent activity in relapsed small cell lung cancer (SCLC). Angiogenesis seems to play an important role in the pathogenesis of SCLC. This study evaluated the safety and efficacy of paclitaxel plus bevacizumab in patients with chemosensitive relapsed SCLC. Methods: Patients with relapsed chemosensitive SCLC with an Eastern Cooperative Oncology Group performance status of 0 to 1 were eligible. They received paclitaxel 90 mg/m2 intravenously on days 1, 8, and 15. Bevacizumab was administered at 10 mg/kg intravenously on days 1 and 15. Cycles were every 28 days. The primary endpoint was progression-free survival (PFS). Secondary endpoints included RRs, toxicity, and overall survival. Correlative studies evaluated vascular endothelial growth factor polymorphisms. Results: Thirty-four patients were enrolled in the study. Median age was 66.5 (range, 38-88) years, male:female: 61.8%:38.2%, Eastern Cooperative Oncology Group performance status 0:1 47.1%:52.9%. Median progression-free survival was 14.7 weeks (equivalent to historical controls). Median survival time was 30 weeks. The overall RR was 18.1%. Stable disease rate was 39.3%, and 45.4% of patients had progressive disease. No unexpected toxicities were noted, and grade 3/4 toxicities were limited to neutropenia, fatigue, and dyspnea. None of the vascular endothelial growth factor polymorphisms evaluated were significantly associated with response. Conclusions: The addition of bevacizumab to paclitaxel does not improve outcomes in relapsed chemosensitive SCLC.

AB - Bevacizumab when combined with carboplatin and paclitaxel improves response rates (RRs) and overall survival in patients with advanced non-small cell lung cancer. Paclitaxel has single-agent activity in relapsed small cell lung cancer (SCLC). Angiogenesis seems to play an important role in the pathogenesis of SCLC. This study evaluated the safety and efficacy of paclitaxel plus bevacizumab in patients with chemosensitive relapsed SCLC. Methods: Patients with relapsed chemosensitive SCLC with an Eastern Cooperative Oncology Group performance status of 0 to 1 were eligible. They received paclitaxel 90 mg/m2 intravenously on days 1, 8, and 15. Bevacizumab was administered at 10 mg/kg intravenously on days 1 and 15. Cycles were every 28 days. The primary endpoint was progression-free survival (PFS). Secondary endpoints included RRs, toxicity, and overall survival. Correlative studies evaluated vascular endothelial growth factor polymorphisms. Results: Thirty-four patients were enrolled in the study. Median age was 66.5 (range, 38-88) years, male:female: 61.8%:38.2%, Eastern Cooperative Oncology Group performance status 0:1 47.1%:52.9%. Median progression-free survival was 14.7 weeks (equivalent to historical controls). Median survival time was 30 weeks. The overall RR was 18.1%. Stable disease rate was 39.3%, and 45.4% of patients had progressive disease. No unexpected toxicities were noted, and grade 3/4 toxicities were limited to neutropenia, fatigue, and dyspnea. None of the vascular endothelial growth factor polymorphisms evaluated were significantly associated with response. Conclusions: The addition of bevacizumab to paclitaxel does not improve outcomes in relapsed chemosensitive SCLC.

KW - Bevacizumab

KW - Paclitaxel

KW - Relapsed small cell

UR - http://www.scopus.com/inward/record.url?scp=78650483125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650483125&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181f77b6e

DO - 10.1097/JTO.0b013e3181f77b6e

M3 - Article

VL - 5

SP - 2008

EP - 2011

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 12

ER -